Insulet Corporation
- Indústria
- Medical Devices
- Bolsa
- EUA
- País / Região
- USA
- Data do IPO
- 15 de maio de 2007
- Funcionários
- 5.400
- Site
- www.insulet.com
Faixa de valuation composta · conservador $110–$120 / justo $120–$160 / otimista $170–$190. A $165, Entre as faixas justa e otimista.
Na publicação $144.94 (31 de maio de 2026)
Dados da EODHD, apresentados na moeda de reporte; apenas para referência, não constitui recomendação de investimento.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
História
Em breveEsta seção está sendo preenchida — volte em breve.
Posição no setor
Em breveEsta seção está sendo preenchida — volte em breve.
Ainda não há análises sobre este ativo no seu idioma.